Triple combination therapy in patients infected with COVID-19
Phase 2
- Conditions
- Coronaviruspatients infected with COVID-19
- Registration Number
- JPRN-jRCTs031190227
- Lead Sponsor
- Tokue Yutaka
- Brief Summary
Since the efficacy of lopinavir, ritonavir, and hydroxychloroquine sulfate was not shown in the research reports from overseas, the recruitment was suspended on June 2, 2020 without any cases. No results were obtained after that because there were no cases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
positive result for COVID-19 detection test
fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan
hospital admission
Exclusion Criteria
past history of hypersensitivity to lopinavir, ritonavir, hydroxychloroquine or oseltamivir
pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method